Spots Global Cancer Trial Database for Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy

Official Title: Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy

Study ID: NCT06027242

Conditions

Gastric Cancer

Immunonutrition

Gastrostomy

Interventions

oral glutamine

Maltodextrin

Study Description

Brief Summary: Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.

Detailed Description: This will be a double-blind, randomized, and placebo-controlled study. At least 80 evaluable patients who are scheduled for gastrectomy for gastric adenocarcinoma cancer will be randomly assigned to the control or treatment group. Each group will have at least 40 patients. The CT scan will be evaluated before surgery and on postoperative day (POD) 90. Moreover, the patient will wear the smart watch to record daily walking steps. Laboratory data will be check before gastrectomy and on POD 90.